The use of eplerenone in in chronic heart failure – experience od Warsaw center Case report
Article Sidebar
Main Article Content
Abstract
The neurohormonal blockade plays a key role in the treatment of chronic heart failure with impaired systolic function. Beta-blockers, angiotensin converting enzyme inhibitors and mineralocorticoid receptor antagonists (MRAs) including spironolactone and eplerenone are the most important drugs. MRA blocking the aldosterone receptor in the kidney increases sodium and water excretion and causes potassium retention. MRA work favorably on the cardiovascular system by inhibiting remodeling and reducing inflammation. Eplerenone is a relatively selective mineralocorticoid receptor antagonist with lower incidence of side effects and better tolerance compared to spironolactone.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Szymański F.M., Filipiak K.J., Mamcarz A. et al.: Eplerenon w codziennej praktyce – aktualne miejsce w terapii i perspektywy stosowania w Polsce. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Folia Cardiol. 2015; 10(4): 288-293.
3. Ponikowski P., Voors A.A., Anker S.D. et al.: Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol. Pol. 2016; 74(10): 1037-1147.
4. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J.: Eplerenone, a selective aldosterone bloker, in mild-to-moderate hypertension. Am. J. Hypertens. 2002; 15: 709-716.
5. Sica D.A.: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev. 2005; 10: 23-29.
6. Pitt B., Zannad F., Remme W.J. et al.: Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
7. Pitt B., Remme W., Zannad F. et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
8. Zannad F., McMurray J.J., Krum H. et al.; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.